ANNUAL FINANCIAL REPORT 2010 2010 - TiGenix

3.11.2 Scenario 1: Existing Shareholders exercise all their Preferential RightsShareholderAfter the Contributionand after the OfferingNumber ofShares %After the Contributionand after the Offeringon fully diluted basis**Number ofShares %ING België NV 5,104,477 5.60% 5,104,477 5.46%Fagus NV 2,526,632 2.77% 2,526,632 2.70%A. van Herk / O.G.B.B.A. van Herk B.V. 2,023,034 2.22% 2,023,034 2.17%Gemma Frisius-Fonds K.U.Leuven NV 1,469,844 1.61% 1,469,844 1.57%Particon B.V. 408,000 0.45% 408,000 0.44%N.V. Industriebank LIOF 408,000 0.45% 408,000 0.44%Limburg Ventures B.V. 240,000 0.26% 240,000 0.26%LRM NV 240,000 0.26% 240,000 0.26%Genetrix Life Sciences A.B. 7,002,454 7.68% 7,002,454 7.50%FCPR Ventech Capital III 6,234,238 6.84% 6,234,238 6.67%LSP III Omni Investment Coöperatief, U.A. 5,334,063 5.85% 5,334,063 5.71%Ysios Biofund I, FCR 5,712,410 6.27% 5,712,410 6.11%Biopartners Capital, S.L. 3,572,928 3.92% 3,572,928 3.82%Novartis Bioventures Ltd. 6,641,886 7.29% 6,641,886 7.11%Roche Finanz AG 6,641,886 7.29% 6,641,886 7.11%CX EBIP Agreement, S.L. 2,286,172 2.51% 2,286,172 2.45%Subtotal 55,846,024 61.29% 55,846,024 59.78%Other Shareholders 35,276,643 38.71% 37,569,135 40.22%TOTAL 91,122,667 100.00% 93,415,159 100.00%3.11.3 Scenario 2: Existing Shareholders exercise no Preferential RightsShareholderAfter the Contributionand after the OfferingNumber ofShares %After the Contributionand after the Offeringon fully diluted basis**Number ofShares %ING België NV 4,253,731 4.67% 4,253,731 4.55%Fagus NV 2,105,527 2.31% 2,105,527 2.25%A. van Herk / O.G.B.B.A. van Herk B.V. 1,685,862 1.85% 1,685,862 1.80%Gemma Frisius-Fonds K.U.Leuven NV 1,224,870 1.34% 1,224,870 1.31%Particon B.V. 340,000 0.37% 340,000 0.36%N.V. Industriebank LIOF 340,000 0.37% 340,000 0.36%Limburg Ventures B.V. 200,000 0.22% 200,000 0.21%LRM NV 200,000 0.22% 200,000 0.21%Genetrix Life Sciences A.B. 5,835,379 6.40% 5,835,379 6.25%FCPR Ventech Capital III 5,195,199 5.70% 5,195,199 5.56%LSP III Omni Investment Coöperatief, U.A. 4,445,053 4.88% 4,445,053 4.76%Ysios Biofund I, FCR 4,760,342 5.22% 4,760,342 5.10%Biopartners Capital, S.L. 2,977,440 3.27% 2,977,440 3.19%Novartis Bioventures Ltd. 5,534,905 6.07% 5,534,905 5.92%Roche Finanz AG 5,534,905 6.07% 5,534,905 5.92%CX EBIP Agreement, S.L. 1,905,144 2.09% 1,905,144 2.04%Subtotal 46,538,357 51.07% 46,538,357 49.82%Other Shareholders 44,584,310 48.93% 46,876,802 50.18%TOTAL 91,122,667 100.00% 93,415,159 100.00%72 • TiGenix • Rights Offering